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Solubles-emyloid protein pmrursors @-APPs) were studied in human brain and ccrcbrospinal fluid (CSF) after partial purification by ion exchange 
chromatography. Proteins were unalysed in immunoblotting experiments using a monoclonal antibody directed against the N-terminal segment 
of the /7-APP 770, and by reverse cnzymography. In the human brain and CSF. a protein which cornigrates with the /3-APP 770 expressed by 
transfected CHO cells was able to inhibit trypsin. 
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1. INTRODUCTION 
Alzheirner’s disease (AD) is a neurodegenerative dis- 
order affecting aged people. The senile plaques are with 
neurofibrillary tangles, characteristic neuropathologi- 
cal features of AD. A peptide of 39-42 amino acids 
called A4 or ,!%amyloid peptide has been identified as a 
major constituent of the amyloid deposits observed in 
senile plaques and in the cerebrovascular angiopathy 
[I J]. The P-amyloid peptide was observed to be part of 
a large precursor containing 695 amino acids @?-APP 
695) which resembles a transmembrane protein [3]. 
Several other /3-APP isoforms have been identified in- 
cluding /3-APP 751. ,&APP 770 and /3-APP 563 [4-71. 
They differ from P-APP 695 by the presence of addi- 
tional sequences in the N-terminal domain which are 
50% homologous with the Kunitz-type serine protease 
inhibitors [4-61. In addition, the /3-APP 563 lacks the 
C-terminal domain, including the transmembrane 
region, present in other P-APPs. Soluble /3-APPs found 
in cell culture medium, human brain extracts or CSF [8] 
are obtained after a proteolytic cleavage of transmem- 
brane P-API%. This cleavage occurs inside the p- 
amyloid peptide [9]. 
In AD, an increase of the expression of ,&APP 
isoforms showing a protease inhibitory activity [S,lO- 
131 might be related to the formation of amyloid de- 
posits, by impending the activity of proteases normally 
involved in the metabolism of/?-APP. This is further 
suggested by the fact that amyloid deposits have been 
reported to occur in transgenic mice carrying a ,&APP 
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751 gene [14]. Amyloid deposits were also found in 
transgenic mice ovcrexpressing the /%amyloid peptide 
[l5]. 
Cultured cells expressing the P-APP isoforms con- 
taining the Kunitz inhibitor domain were previously 
reported to inhibit trypsin, a well-known serine protease 
[6,I 61. In this study, we have investigated the inhibition 
of trypsin by soluble P-APPs found in human brain 
extracts and CSF in comparison to that found in the 
culture medium of transfected cells. 
2. MATERIALS AND METHODS 
The p-APP 770.pKCK3 expression shuttle and a pSV2KE0 neo- 
mycin resistance gene vector wcrc cotranskcted into CHO cells using 
the calcium phosphate precipitation method [ 171. On day 2 after trans- 
fection, trunsfected cells wcrc selected by growing them in the presence 
of GO0 pufi/rnl of geneticin (G418). Expression of p-APP 770 wus 
measured in imniunoblolling experiments using u monoclonal anli- 
body raised against the N-terminal domain of,&APP 770. This mouse 
I&A monoclonttl antibody was obtained after inoculation ofa bacterial 
fusion protein between /?-galactosidase and a fragment of APP 770 
encompassing the sequence between amino acids 81 and 481, Having 
established a CHO cell population expressing the @-APP 770, this 
mixed populaticn was subjected to limiting dilution to produce indi- 
vidual clonal cell lines. The monoclonal cells were then cultured for 
24 h in Ham Fl2 medium (,Gibco) without foetal calf serum. This 
culture medium, containing secreted fi-APP 770, was desalted by Se- 
phadex G25 chromatography and concentrated by jyophylisation 
prior to SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
One gram of cercbrul frontal cortex isolated from normal human 
brnin was homogcneized using a Dounce homogenizer, in 4 ml of 50 
mM Tris-HCI (pH 7.6), I mM EDTA, I pdrnl Ieupcptin, 5 PgIrnl 
aprotinin (buffer A) and centrifuged for one hour at 50,000 x 6, The 
supernatant of the brain homogenate was further analysed. CSF from 
non-AD patients was precipitated by GO% (NH.,)ISO., and centrifuged 
for 30 miu ai 10,000 x 8. Tine prilet was resuspended tind dialysrd 
against buffer A. The soluble frdCtiOn of the brain homogenate and 
CSF were applied onto DEAE-cellulose column (Whatman) prcvi- 
ously equilibrated in buffer A. Proteins were elutcd by buffer A con- 
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taininy IS0 mM, 300 mM or 600 mM NaCI. The fraclion of CSF 
clurcd by 0.3 M NaCl was furlhcr analyzed by HPL.Ccllromatogr;iphy 
on Mono-Q column (Pharmacia) as dcscribcd by Palmun ct al. [IS]. 
All samples were desalted and conccnlratcd prior to SDS-PAGE. 
Proteins wcrc clccirophorcscd on 7.5% polyacrylamide gels in 
Lacmmli buffer and wcrc transferred to nilroccllulose [19]. After a 
blocking step in 5% non-fat dry-milk, the nitrocellulosc was incubated 
with the specific anti-APP monoclonal antibody, a biotinylatcd goat 
anti-mouse IgA (Sigma) and developed by the strcplavidin-alkaline 
phosphatase conjugated system (Dochringcr). For rcvc’rsc enzymop- 
raphy [20], gels were ruII in non-dcnalureting conditions (i.c. in ~hc 
absence ol’P-mcrcaptorihanol and without boiling step). After clccrro- 
phorcsis, gels were washed at room tumpcralurc in 100 mM Tris-HCI 
(pH Kl), 2.5% Triton X-IOOand tinally in IOOmM Tris-HCI. The gols 
were then layered 011 0.8% iigar gd conlsining I5 mg/ml non-fat 
dry-milk solubilized in 100 mM Tris-HCI (pH 8.1) and 50 r&ml 
trypsin (Sigma) and incubulod for I6 h at 37°C. Trypsin was able to 
digest and clarify casein bul not whcrc trypsin inhibition occurred. 
3. RESULTS 
The inhibition of trypsin by soluble P-APPs found in 
human brain and CSF was compared to that of secreted 
P-APP 770 expressed by transfected CHO cells. A 
50,000 x 6 supernatant of a human brain homogenate 
and total CSF were analysed in immunoblotting experi- 
ments together with the soluble form of the P-APP 770 
found in the culture medium of transfected CM0 cells. 
Fig. IA shows that two proteic bands (0.~) were speci- 
fically recognized by the anti-APP monoclonal antibody 
in brain and CSF. The upper band comigrates with the 
/5’-APP 770 found in the culture medium of CHO cells 
transfected with the corresponding cDNA sequence. 
Additional bands (lane 2) were also detected when the 
first specific monoclonal antibody was not added (lane 
L?), and therefore are due to the revelation system used. 
Fig. IS shows the analysis of the same samples by 
reverse enzymography, allowing one to measure the 
ability of a protein to inhibit the trypsin-induced diges- 
tion of casein. p-APP 770 found in the culture medium 
of transfected CHO cells is able to inhibit trypsin, as it 
contains the Kunitz protease inhibitor domain [13]. In 
A 6 
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Fig. 1. Weslem blot analysis after SDS-PAGE (A) or reverse cn- 
zymopraphy after electrophoresis in non-dcnaluralingconditions (B). 
(Lane 1) Culture medium from /3-APP 770 CHO irnnsfccied cells. 
(Lane 2) Soluble fraction of brain homogenale. (tine 3) CSF. (Lane 
4) Soluble Fraction of brain homogenate revealed without the first 
specific monoclonal antibody. 
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Fig. 2. Purification of fi-APPs from ihc soluble fraction of brain 
homogcnau, USillg DEAE chromalogrirphy. (A) Wcstcrn blot analy- 
sis. (B) Reverse enxymography. (Lxx I ) 0. I5 M NKI clutccl proleins. 
(Lane 2) 0.30 M NaCl clutcd proteins. (Lane 3) 0.60 M NaCl cluicd 
proteins. 
the human brain, an inhibitory ac 2ty (0) cornigrates 
with that found in the culture medium of transfected 
cells. While the situation in CSF is far more complex. 
an inhibitory activity is also detected at the same molec- 
ular weight. 
In order to clarify the results, we decided to purify the 
proteins recognized by the monoclonal antibody using 
anionic chromatography on DEAE-cellulose and a 
Mono-Q HPLC column. Fig. 2 shows that the ion cx- 
change chromatography was able to dissociate the spe- 
cific immunolabelling from the non-specific one. Fig. 
2A shows that the doub!et specilically recognized by the 
anti-APP monoclonal antibody (0,~) is eluted at 0.3 M 
NaCI. The inhibitory activity (0) is recovered in the 
same fraction at a molecular weight which could cor- 
respond to the high molecular form of the two proteins 
recognized by the monoclonal antibody (Fig. 26). 
The human CSF was submitted to the same analysis 
after ammonium sulfate precipitation (Fig. 3). As for 
human brain, the doublet recognized by the antibody 
was eluted from the DEAE column in the fraction con- 
taining 0.3 M NaCl (Fig. 3A, lane 3). In reverse en- 
zymography, many different inhibitory activities were 
detected in the same fraction. It is the reason why we 
further rechromatographed this 0.3 M fraction on a 
HPLC Mono-Q co!umn. At 0.G M NaCl concentration, 
the proteic bands recognized by the antibody were 
eluted (Fig. 3A, lane 4). In reverse enzymography, this 
fraction was shown to exhibit a trypsin inhibitory activ- 
ity concentrated in two proteins (Fig. 3B, lane 4). A 
strong inhibition of trypsin was detected at a molecular 
weight corresponding to the high molecular weight @- 
APP isoform recognized by the anti-APP monoclonal 
antibody. A wc’ak inhibitory signal was also detected in 
a region of the gel where the second APP isoform is 
found. In the total CSF, however, this inhibitory activ- 
ity was not detected (Fig. 3B, lane I), in spite of the 
recognition of the low molecular weight APP isoform 
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Fig. 3. Purilication ol’&APPs from CSF by DEAE- and Mono-Q- 
chromatography. (A) Western blot analysis. (B) Revcrsc cnzymog- 
raphy. (Lane I) Total CSF. (Lane 2) (NH&SOJ precipitated CSF. 
(L;~nc 3) 0.3 M clu~cd I’ritction. (Lane 4) Mono-Q cl&d fraction. 
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by the specific monoclonal antibody (Fig. 3A, lane 1). 
Therefore, this inhibition of trypsin seems unrelated to 
ADP. 
4. DISCUSSION 
Molecular cloning allowed the identification of p- 
APP isoforms containing sequences in their extracel- 
lular domain which show homology with serine pro- 
tease inhibitors of the Kunitz Pdmily. Using chromo- 
genic substrates, transfectcd cells expressing the p-APP 
770 were shown to exhibit a trypsin inhibitory activity 
[G]. The protease inhibitory properties of the /3-APP 75 1 
expressed as a bacterial fus’ion product were also dem- 
onstrated by protease inhibition assays using chromo- 
genic substrates [21]. While very sensitive, these assays 
do not identify the proteins carrying the inhibitory ac- 
tivhy. The reverse enzymography is a protease inhibi- 
tion assay which allows the identification of proteins 
showing inhibitory activities, after their isolation by 
non-denaturating gel elcctrophoresis. Using this pro- 
tease inhibition assay, we report here that a protein 
found both in the human brain and CSF which is re- 
cognized by an anti-APP monoclonal antibody is able 
to inhibit trypsin. This protein which comigrates with 
the/%APP 770 expressed by transfected cells most prob- 
ably corresponds to a /3-APP isoform containing the 
Kunitt protease inhibitor (KPI) domain. In the same 
way, an immunoblotting analysis of the human CSF 
using an anti- KPI antibody, showed that only the high 
molecular weight p-APP isoform contains the KPI 
domain [ 181. 
In AD, an increase of the expression of p-APP 
isoforms showing a protease inhibitory activity, as 
reported in several studies [lo-13,221. might be related 
to ihe formation of amytoid deposits, sicce smyloid 
deposits have been reported to occur in transgenic mice 
carrying a /3-APP 751 gene [14]. While the protease 
specificity of the KPI domain has been investigated in 
vitro [233, the identification of the physiological sub- 
strate of the cerebral APP isoforms containing the KPI 
domain awaits further investigations. 
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